The Validation of a Novel Adherence Method for Oral Oncolytics



Status:Active, not recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/15/2019
Start Date:June 7, 2017
End Date:March 31, 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The long-term goal of this research is to apply technologic approaches to improve the use of
oral oncolytics. The objective of this study is to assess patient adherence to oral
oncolytics and to validate a currently available smart phone application (iRxReminder)
partnered with an automated dispensing device, a "Pod", in affecting patient adherence. The
rationale for this study is that medication adherence to oncolytics varies and strategies are
needed to improve it.


Inclusion Criteria:

- Must be > 18 years of age

- Must have a smart phone

- Must be able to have their oral oncolytic filled at the University of Michigan
Comprehensive Cancer Center pharmacy and be newly prescribed Capecitabine (Xeloda).

Exclusion Criteria:

- Patients who do not have a smart phone

- Patients who have a serious mental illness or cognitive impairment, e.g., psychosis or
dementia.

- Patients who do not speak English

- Patients who cannot fill their oral oncolytic prescription at the University of
Michigan Comprehensive Cancer Center Pharmacy
We found this trial at
1
site
University of Michigan Comprehensive Cancer Center
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Dawn Owen, M.D., Ph.D.
Phone: 734-232-6667
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials